ArticleDiscover oncology2025
LINC01063 promotes colon cancer progression via the miR-134-5p/KRAS axis and serves as a prognostic biomarker.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA DLGAP1-AS2 promotes ESCC progression and indicates unfavorable prognosis via the miR-101-3p/EZH2 axis.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in treatment, the prognosis of colon cancer is still unsatisfactory, and there is an urgent need for reliable biomarkers and mechanistic studies. The role of long non-coding RNAs (lncRNAs) in tumor progression is well established, but the prognostic value and mechanism of LINC01063 in colon cancer are unclear.
methodsWe analyzed samples of colon cancer tissues and paracancerous normal tissues from 116 patients and performed functional experiments in the RKO/HCT116 cell line. The expressions of LINC01063 and miR-134-5p were measured using qRT-PCR. Clinical significance was assessed by statistical methods, and their interactions were verified by dual luciferase assay. The biological effects were evaluated by CCK-8, Transwell, and apoptosis assays.
resultsLINC01063 was upregulated in cancer tissues, associated with the TNM staging system and lymph node dissemination, and an independent predictor of poor prognosis. LINC01063 acts as a "molecular sponge" to adsorb miR-134-5p and deregulate its inhibitory effect on KRAS. Knockdown of LINC01063 inhibited cell proliferation/invasion and promoted apoptosis, partially reversed by miR-134-5p inhibition. LINC01063 sponged miR-134-5p to relieve inhibition of KRAS, with KRAS mediating its pro-tumor effects.
conclusionIn this study, we demonstrated that LINC01063 can be used as an independent prognostic marker for colon cancer and explored its promotion of colon cancer cancer progression through the miR-134-5p/KRAS axis. Future studies will focus on in vivo validation and elucidation of downstream signaling cascades, while clinically, LINC01063 holds potential as a prognostic indicator and a therapeutic target for KRAS-mutant colon cancer, aiding in personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.